Q-Med has received 29.1 MUSD from Medicis

Q-Med has received 29.1 MUSD from Medicis

Due to the fact that the American regulatory authority, the U.S. Food and Drug
Administration (FDA), has approved PERLANE for sales in the USA, Q-Med has
received 29.1 MUSD from Medicis (197.4 MSEK). The payment is the last additional
purchase sum from the agreement that was entered into with Medicis in 2003. The
agreement has thereby generated a total purchase sum of 160 MUSD. Furthermore,
Q-Med has exclusive manufacturing rights for the North American market for ten
years.

In connection with the payment, the previous provision of 34.5 MSEK for research
and development costs will be reversed.

The first deliveries of PERLANE will soon be made.

Queries should be addressed to: 
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: 070-974 90 15

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets and sells primarily medical
implants. The majority of the products are based on the company's patented
technology, NASHA™ for the production of stabilized non-animal hyaluronic acid. 
The product portfolio today contains: RESTYLANE for the filling out of lips and
facial wrinkles and for facial contouring, DUROLANE, for the treatment of
osteoarthritis of the hip and knee joints, DEFLUX for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
ZUIDEX, for the treatment of stress urinary incontinence in women and SOLESTA,
for the treatment of fecal incontinence. Sales are made through the company's
own subsidiaries or distributors in over 70 countries. Q-Med today has just over
600 co-workers, with approximately 400 at the company's head office and
production facility in Uppsala, Sweden. Q-Med AB is listed in the Large Cap
segment of the OMX Nordic Stock Exchange in Stockholm.

NASHA, DUROLANE, SOLESTA, ZUIDEX, IMPLACER, DEFLUX and all product names within
the RESTYLANE family are trademarks that belong to Q-Med AB.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web:
www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia,
Inc.